250 related articles for article (PubMed ID: 2601036)
1. [Multiple myeloma].
Kanoh T
Rinsho Ketsueki; 1989 Aug; 30(8):1212-5. PubMed ID: 2601036
[TBL] [Abstract][Full Text] [Related]
2. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
3. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
4. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
[TBL] [Abstract][Full Text] [Related]
5. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
6. IgD multiple myeloma. A report of three cases.
Martini R; Santini S; Bottari G
Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286
[TBL] [Abstract][Full Text] [Related]
7. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
8. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
9. IgD myeloma with myelofibrosis and amyloidosis.
Udoji WC; Pemmaraju S
Arch Pathol Lab Med; 1977 Jan; 101(1):10-3. PubMed ID: 401635
[TBL] [Abstract][Full Text] [Related]
10. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
12. High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study.
Fenk R; Schneider P; Kropff M; Huenerlituerkoglu AN; Steidl U; Aul C; Hildebrandt B; Haas R; Heyll A; Kobbe G;
Br J Haematol; 2005 Aug; 130(4):588-94. PubMed ID: 16098074
[TBL] [Abstract][Full Text] [Related]
13. [Current results of chemotherapy in multiple myeloma].
Sezaki T
Gan To Kagaku Ryoho; 1989 May; 16(5):1997-2003. PubMed ID: 2658839
[TBL] [Abstract][Full Text] [Related]
14. [A case of gastric amyloidosis developing into Bence-Jones type multiple myeloma, treated effectively by cyclo-VAMP chemotherapy].
Ayabe T; Maekawa I; Ashida T; Taruishi M; Shibata Y; Namiki M
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2399-403. PubMed ID: 8259860
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma: the National University Hospital (NUH) experience.
Lim HL; Teo CP; Wong K; Kuperan P; Suri R; Tan YO; Kueh YK
Singapore Med J; 1994 Aug; 35(4):371-3. PubMed ID: 7899894
[TBL] [Abstract][Full Text] [Related]
16. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
Bettini R; Tonolini M; Bernasconi M
Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
[TBL] [Abstract][Full Text] [Related]
18. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
20. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
